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Introduction: Treatment patterns and cost implications of increased 
positron emission tomography imaging use since Medicare approval 
in 1998 are not well understood. We examined rates of surgery, radio-
therapy, and chemotherapy and inpatient and total health care costs 
between 1998 and 2005 among Medicare beneficiaries with non–
small-cell lung cancer.
Methods: Patients in this retrospective cohort study were 51,374 
Medicare beneficiaries diagnosed with non–small-cell lung cancer 
between 1996 and 2005. The main outcome measures were receipt of 
surgical resection, radiotherapy, and chemotherapy and inpatient and 
total health care costs within 1 year of diagnosis.
Results: Between 1996–1997 and 2004–2005, the proportion of 
patients undergoing surgical resection decreased from 29% to 25%, 
the proportion receiving radiation therapy decreased from 49% to 
43%, and inpatient costs decreased from $28,900 to $26,900. The 
proportion of patients receiving chemotherapy increased from 25% to 
40% and total costs increased from $47,300 to $52,200 (p < 0.001 for 
all comparisons). Changes in use and costs remained after adjustment 
for shifting demographic characteristics during the study period.
Conclusions: Adoption of positron emission tomography between 
1998 and 2005 was accompanied by decreases in rates of surgery 
and radiotherapy and in short-term inpatient costs among Medicare 
beneficiaries with non–small-cell lung cancer, although there was an 
increase in chemotherapy and overall costs.
Key Words: Carcinoma, Non–small-cell lung cancer, Health care 
costs, Positron emission tomography.
(J Thorac Oncol. 2014;9: 512–518)
Positron emission tomography (PET) is an advanced imaging modality used in the clinical diagnosis, stag-
ing, and follow-up of non–small-cell lung cancer (NSCLC). 
Randomized controlled trials of PET use in initial staging of 
NSCLC have suggested that PET can detect occult metastatic 
disease and avoid futile resection.1–3 Epidemiologic studies 
suggest that PET is associated with upstaging of NSCLC in 
clinical practice.4,5 The presumption that appropriate detection 
of occult metastatic disease should reduce futile rates of local-
ized tumor control and associated health care costs has been 
examined in a single randomized controlled trial6 and remains 
an open question at the population level. Whether increased 
PET use among Medicare beneficiaries with NSCLC has 
affected rates of localized control or its associated costs 
remains an important policy question.
In this study, we examined rates of local surgical resec-
tion, radiotherapy, and chemotherapy and inpatient and total 
health care costs among Medicare beneficiaries with NSCLC. 
Specifically, we tested the hypotheses that, between 1998 and 
2005, the Medicare population with NSCLC experienced reduc-
tions in the use of surgical resection and radiotherapy and in 
short-term inpatient surgery costs and overall health care costs.
PATIENTS AND METHODS
Data Source
Data are from the Surveillance Epidemiology and End 
Results (SEER)-Medicare linked data. SEER-Medicare is a 
collaborative effort between the National Cancer Institute and 
the Centers for Medicare & Medicaid Services that links rou-
tinely collected population-based data from cancer registries 
across the United States to Medicare administrative data and 
health care claims.7 The SEER data include demographic and 
incident cancer characteristics, including grade and stage, 
for approximately 25% of the U.S. population with cancer. 
Medicare provides health insurance for 97% of people 65 
years and older in the United States, and the data reflect health 
care services used and comorbid conditions. SEER-Medicare 
data have been used previously to examine factors that affect 
the quality of care for patients with cancer, including sociode-
mographic characteristics, physician and hospital characteris-
tics, surgery, chemotherapy, radiation, comorbid conditions, 
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complications, screening, relapse, and costs.8–18 The Office of 
Human Research Ethics at the University of North Carolina at 
Chapel Hill approved this study.
Study Population
We analyzed SEER-Medicare data from the 12 SEER 
registries that were active from 1996 onward. We included 
all patients from these registries who had a diagnosis of 
cancer of the lung and bronchus with microscopically con-
firmed NSCLC histology between 1996 and 2005, were 66 
years or older at the time of the diagnosis, and had Medicare 
Part A and Part B coverage without participating in a health 
maintenance organization or in Medicare Part C during the 
year before and after diagnosis or until death. We excluded 
patients for whom a diagnosis was determined at autopsy or 
death or who had another diagnosis of malignancy in the year 
before the NSCLC diagnosis. To help ensure full acquisition 
of cancer-related claims, we also required that patients have a 
primary diagnosis of lung cancer (International Classification 
of Diseases, Ninth Revision, Clinical Modification 162.2–
162.9 or 231.2) on an inpatient, outpatient, or carrier-based 
Medicare claim within 2 months of the SEER diagnosis.
Study Variables
The primary study outcomes were surgical resection, 
receipt of radiotherapy, and inpatient health care costs within 1 
year of the SEER diagnosis. Additional treatment and cost vari-
ables included receipt of chemotherapy, use of PET, and overall 
health care costs. We obtained treatment and health care costs 
from claims data from 2 months before through 12 months 
after the month of the NSCLC diagnosis in the SEER data. 
We identified receipt of each treatment modality using previ-
ously defined sets of Healthcare Common Procedure Coding 
System codes and International Classification of Diseases, 
Ninth Revision, Clinical Modification codes (Supplemental 
Table, Supplementary Digital Content 1, http://links.lww.com/
JTO/AXX).19,20 We identified surgical procedures using claims 
for lung resection from inpatient, outpatient, or carrier claims 
files.19 We identified receipt of chemotherapy using claims 
from outpatient, carrier, and durable medical equipment claims 
files.20 We used outpatient and carrier claims data to identify 
receipt of radiation therapy.20 We also used outpatient and car-
rier claims from 2 months before through 4 months after the 
SEER diagnosis to identify use of PET to coincide with the 
4-month follow-up period used by SEER to provide cancer 
stage.21 Medicare payment information was available in each 
claim file; we summed line-item payments (from home health, 
hospice, and outpatient files), total claim payment amounts 
(from carrier and durable medical equipment files), or total 
reimbursement plus total daily per diem charges (from inpa-
tient files) and adjusted all payments to 2008 dollars using the 
health care component of the Consumer Price Index.
We obtained all remaining variables from the SEER 
Patient Entitlement and Diagnosis Summary File. We extrapo-
lated SEER cancer stage to the American Joint Committee on 
Cancer third edition staging system to provide a common stag-
ing system throughout the study period.5 Survival at 2 years 
was obtained from the SEER-based death date. Demographic 
variables included age, sex, race, ethnicity, marital status, and 
local census tract characteristics (i.e., metropolitan urban or 
rural status, percentage not finishing high school, percentage 
below the poverty line, and percentage of black race).
Statistical Analysis
We defined discrete cohorts to represent the pre-PET 
period (1996–1997), the initial PET period (2000–2001), and 
the late PET period (2004–2005). We compared demographic 
and treatment characteristics using chi-square tests for cat-
egorical variables and Kruskal-Wallis nonparametric tests for 
continuous variables. We used multivariable logistic regres-
sion models (logit) to examine the use of surgical resection, 
radiation therapy, and chemotherapy over time using 1996–
1997 as the reference period and modeling subsequent years 
as categorical variables.
We analyzed health care costs using multivariable ordi-
nary least squares regression models of total Medicare pay-
ments in the inpatient, non-inpatient, and total claims files 
between 1996 and 2005. We modeled Medicare payments as 
logged costs to adjust for left-skewed cost data and to avoid 
nonnormally distributed error terms. We calculated relative 
percentage differences in costs as described by Kennedy.22
All regression models controlled for disease stage and 
demographic characteristics. In order for all observations 
to use sociodemographic variables from the 2000 census, 
we used 1996 as the earliest year in the regression analyses. 
Patient SEER registry was included as a control variable in all 
regressions to mitigate the effects of regional differences in 
treatment practices and costs.7
We performed sensitivity analysis of cost regressions 
by analyzing short-term costs (within 4 mo of diagnosis) to 
provide a more direct surrogate for initial surgical costs. All 
results were considered significant at p less than 0.05. We used 
SAS version 9.2 (SAS Institute, Cary, NC) for all analyses.
RESULTS
Of the 159,201 Medicare beneficiaries diagnosed with 
cancer of the lung and bronchus by SEER between 1996 
and 2005, 58,575 met the eligibility criteria for the analy-
sis (Supplemental Figure, Supplementary Digital Content 1, 
http://links.lww.com/JTO/AXX). Later NSCLC cohorts had a 
larger percentage of patients who were older than 80 years, 
were women, had more than 1 comorbid condition, and were 
not married (Table 1; all p < 0.001).
As shown in Table 2, between 1996–1997 and 2004–
2005, decreasing proportions of patients underwent surgical 
resection (29.1% versus 24.7%; p < 0.001) and radiation 
(49.4% versus 42.9%; p < 0.001). By contrast, the propor-
tion of patients receiving chemotherapy increased signifi-
cantly from 25.1% to 40.4% (p < 0.001). During the same 
period, total costs per patient increased from $47,300 to 
$52,200 (p < 0.001). Increasing costs were entirely driven 
by non-inpatient costs ($18,400 versus $25,300; p < 0.001). 
Inpatient costs in the year after diagnosis decreased by $2200 
per patient by 2000–2001 (p < 0.001). The overall proportion 
of patients undergoing surgical resection or radiation began 
to decrease by 2000, whereas chemotherapy use increased 
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throughout the study period (Figure 1). Inpatient surgery 
costs decreased between 1998 and 2003, whereas nonsur-
gical inpatient costs remained stable over the study period 
and total costs increased steadily between 2000 and 2004 
(Figure 2). The average cost of chemotherapy and radiation 
therapy combined constituted a relatively small and stable 
cost over the course of the study.
After adjustment for shifting patient demographic char-
acteristics, and using 1996–1997 as the reference, the odds of 
undergoing surgical resection or radiation therapy decreased 
TABLE 1.  Demographic Characteristics of the Study Population by Cohort
Characteristic
Pre-PET Cohort,  
1996–1997 (n = 9638)
Initial PET Cohort,  
2000–2001 (n = 9551)
Post-PET Cohort,  
2004–2005 (n = 11,814) p
Age >80 yr, n (%) 1624 (16.9) 2006 (21.0) 2837 (24.0) <0.001
Male, n (%) 5332 (55.3) 5140 (53.8) 6064 (51.3) <0.001
Black race, n (%) 763 (7.9) 786 (8.2) 964 (8.2) 0.70
Comorbid conditions, n (%) <0.001
  0 5532 (57.4) 4988 (52.2) 5751 (48.7)
  1 2568 (26.6) 2726 (28.5) 3456 (29.3)
  ≥2 1538 (16.0) 1837 (19.2) 2607 (22.1)
Census tract characteristics 
(highest quartile)
 Did not complete high 
school
2026 (26.1) 2070 (25.5) 2399 (22.8) <0.001
 Below poverty line 2005 (25.8) 2007 (24.7) 2423 (23.1) <0.001
 Percent black 2019 (26.0) 1995 (24.6) 2437 (23.2) <0.001
Married, n (%) 5385 (55.9) 5064 (53.0) 6108 (51.7) <0.001
Metropolitan, n (%) 8294 (86.1) 8179 (85.6) 10,165 (86.0) 0.63
U.S. geographic region <0.001
  Midwest 3377 (35.0) 3314 (34.7) 3822 (32.4)
  Northeast 1479 (15.4) 1374 (14.4) 1796 (15.2)
  South 678 (7.0) 649 (6.8) 777 (6.6)
  West 4104 (42.6) 4214 (44.1) 5419 (45.9)
PET, positron emission tomography.
TABLE 2.  Outcomes, Treatments, and Costs by Cohort
Characteristic
Pre-PET Cohort,  
1996–1997 (n = 9638)
Initial PET Cohort,  
2000–2001 (n = 9551)
Post-PET Cohort,  
2004–2005 (n = 11,814) p
Any PET scan, n (%) 23 (0.2) 1674 (17.5) 6314 (53.5) <0.001
Distance to PET facility < 40 miles, n (%) — 4511 (47.2) 6075 (51.4) <0.001
Disease stage, n (%) <0.001
  Localized disease (stage I–IIIA) 3173 (32.9) 3031 (31.7) 4342 (36.8)
  Advanced disease (stage IIIB–IV) 4303 (44.7) 4907 (51.4) 6212 (52.6)
  Unstaged 2162 (22.4) 1613 (16.9) 1260 (10.7)
Overall 2-year survival, n (%) 2766 (28.7) 2730 (28.6) 3529 (29.9) 0.07
Treatment, n (%)
  Any resection 2803 (29.1) 2529 (26.5) 2913 (24.7) <0.001
  Any radiation 4765 (49.4) 4685 (49.1) 5066 (42.9) <0.001
  Any chemotherapy 2423 (25.1) 3257 (34.1) 4771 (40.4) <0.001
  No treatment 7519 (22.0) 7393 (22.6) 8895 (24.7) <0.001
Costs, mean, $a
  Inpatient 28,924 26,749 26,944 <0.001
  Non-inpatient 18,411 20,329 25,266 <0.001
 PETa 0 308 741 <0.001
Total 47,335 47,079 52,209 <0.001
aPET costs are a subset of non-inpatient costs. All costs are expressed in 2008 U.S. dollars.
PET, positron emission tomography.
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and the odds of receiving chemotherapy increased between 
2001 and 2005 (Table 3). Surgical resection was more likely 
among patients who had localized disease or were married 
and was less likely among older patients, men, patients from 
census tracts with lower levels of education, and patients 
with advanced disease or multiple comorbid conditions. Both 
radiation therapy and chemotherapy were more likely among 
patients with advanced disease and were less likely among 
patients older than 80 years (all p < 0.001).
Total non-inpatient and overall mean costs per patient 
increased between 1996–1997 and 2005. After adjustment for 
shifting demographic characteristics and using 1996–1997 as 
the pre-PET baseline, 12-month inpatient costs in the year after 
diagnosis did not change significantly, but the coefficients for 
years 2000, 2001, and 2004 suggested a trend toward decreas-
ing inpatient costs (Table 4). Sensitivity analyses of inpatient 
costs, in which we limited the cost analysis to the 4 months 
after diagnosis, showed a significant 12% decrease in inpa-
tient costs. Total health care costs increased by 10% by 2005, 
driven entirely by increases in non-inpatient costs. Localized 
disease, black race, and comorbidity increased both inpatient 
and overall health care costs.
In sensitivity analyses, the presence of localized dis-
ease was more strongly associated with inpatient costs within 
4 months than at 12 months. Overall costs and non-inpatient 
cost estimates were unaffected by analyses using a 4-month 
versus 12-month cost window.
DISCUSSION
After controlling for shifting demographic characteris-
tics, we found that Medicare beneficiaries with NSCLC were 
less likely after the adoption PET to undergo surgery or radia-
tion therapy and had lower mean inpatient costs between 1998 
and 2005. However, during the same period, the use of chemo-
therapy and non-inpatient expenditures increased rapidly, more 
than offsetting potential savings in inpatient expenditures.
Estimates from 2003 through 2005 suggest a rela-
tively stable reduction of 12% in inpatient expenditures, 
which in 2004–2005 would have amounted to an approxi-
mately $3200 reduction per patient. During the same period, 
increased  non-inpatient costs counteracted any net cost sav-
ings. Interpretation of cost redistribution may be complicated 
by other changes in oncology practice that occurred during 
the study period, including a global shift of cancer care from 
inpatient to outpatient settings23 and evolving guidelines sup-
porting increased chemotherapy use in patients with NSCLC.24 
We observed a consistent increase in chemotherapy use before, 
during, and after the study period that did not appear tempo-
rally correlated with PET adoption. Alternatively, the observed 
decrease in surgical and associated inpatient costs could be 
due, in part, to a growing proportion of patients with multiple 
comorbid conditions in later cohort years who might be denied 
a surgical procedure for medical reasons unrelated to can-
cer. However, we did not observe a concomitant substitution 
or increase in radiation therapy, typically used in medically 
inoperable patients, which would argue against an increase in 
comorbidity as the sole explanation for our findings.
It has been largely accepted that PET may reduce futile 
thoracotomies that might otherwise occur when a patient who 
presents with occult metastatic disease undergoes local, defin-
itive treatment for incurable disease.1 It should be noted, how-
ever, that PET scans can also result in false-positive results 
and could potentially cause cancellation of surgical resec-
tion for some patients. Because of appropriate, selective PET 
administration among patients with early-stage, less aggres-
sive disease, demonstrating a direct association of PET with 
reduced thoracotomy and radiotherapy rates is difficult using 
a nonexperimental approach. Nonetheless, our study provides 
supporting evidence that PET-induced stage migration may 
have reduced rates of futile thoracotomy and radiation, accom-
panied by a decrease in subsequent inpatient health care costs.
Alternative explanations for decreasing surgery rates 
include changes in general oncology practice patterns unre-
lated to PET use,23 changing guidelines,24 and evidence 
suggesting the benefit of chemotherapy, and improvements 
FIGURE 1.  Treatment patterns among Medicare benefi-
ciaries with non–small-cell lung cancer, 1996–2005. PET, 
positron emission tomography.
FIGURE 2.  Mean treatment costs among Medicare beneficiaries 
with non–small-cell lung cancer, 1996–2005.
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in management of side effects. Alternatively, the use of 
 higher-resolution computed tomographic scans or medi-
astinoscopy, increased appreciation of surgical morbidity 
in patients with advanced disease, or an aging and sicker 
population may have shifted the risks and benefits, actual 
or perceived, of local versus systemic treatment during the 
study period. In theory, a reduction in futile thoracotomy 
could lead to an inadvertent increase in the use of chemo-
therapy. Making this scenario less likely is the observation 
that chemotherapy rates increased before PET adoption. 
Nonetheless, the potential for PET to shift care from thora-
cotomy to chemotherapy has not previously been appreciated 
within small randomized trials and represents an important 
consideration when evaluating the overall effect of PET use 
on health care expenditures.
Our study has several limitations. First, we were only 
able to identify PET scans reimbursed by Medicare. To mini-
mize missed claims, we limited all analyses to Medicare 
beneficiaries who were likely to have complete claims data. 
Second, the SEER registry overrepresents patients who are 
nonwhite, live in areas with less poverty, and live in urban 
areas, which may limit the generalizability of the findings.7 
In addition, changes in treatment patterns and costs between 
SEER registries may vary. To help mitigate these differences, 
we included registry as a control variable in all regression 
analyses. Third, Medicare claims include intravenous chemo-
therapy and oral equivalents, but not chemotherapy or sup-
portive medications filled as outpatient prescription. Oral 
chemotherapy can pose a substantial cost to patients and 
outside insurers, and our analysis likely underestimates the 
TABLE 3.  Regression Analysis of Receiving Any Resection, Radiation, or Chemotherapy between 1996 and 2005 (n = 43,695)
Characteristic
OR (95% CI)
Any Resection Any Radiation Any Chemotherapy
Year of diagnosis
  1996/1997 1.00 [Reference] 1.00 [Reference] 1.00 [Reference]
  1998 0.93 (0.84–1.04) 0.97 (0.85–1.11) 1.30 (1.19–1.43)a
  1999 1.04 (0.91–1.18) 0.95 (0.86–1.05) 1.52 (1.34–1.72)a
  2000 0.98 (0.88–1.10) 0.96 (0.90–1.03) 1.68 (1.58–1.79)a
  2001 0.87 (0.79–0.96) 0.97 (0.92–1.03) 1.72 (1.59–1.87)a
  2002 0.86 (0.76–0.97) 0.85 (0.79–0.93)a 1.89 (1.75–2.04)a
  2003 0.83 (0.74–0.93) 0.81 (0.77–0.85)a 2.08 (1.94–2.23)a
  2004 0.72 (0.63–0.81)a 0.81 (0.73–0.89)a 2.52 (2.35–2.70)a
  2005 0.75 (0.67–0.84)a 0.76 (0.69–0.84)a 2.39 (2.21–2.57)a
Localized disease 7.14 (5.75–8.88)a 0.73 (0.68–0.79)a 0.54 (0.49–0.61)a
Advanced disease 0.30 (0.24–0.37)a 1.40 (1.29–1.51)a 1.21 (1.09–1.34)a
PET facility >40 miles away 1.09 (0.97–1.23) 1.02 (0.96–1.08) 1.02 (0.93–1.12)
Age > 80 yr 0.44 (0.40–0.47)a 0.76 (0.72–0.81)a 0.34 (0.32–0.36)a
Black race 0.68 (0.59–0.77)a 1.12 (1.04–1.21) 0.96 (0.88–1.05)
Comorbid conditions
  1 0.90 (0.82–0.99) 0.94 (0.89–0.99) 0.87 (0.84–0.91)a
  >1 0.71 (0.65–0.77)a 0.88 (0.85–0.91)a 0.61 (0.57–0.67)a
Census tract–level percentage of population with less than high school education
  Quartile 2 0.79 (0.72–0.88)a 1.02 (0.99–1.06) 0.97 (0.94–1.00)
  Quartile 3 0.72 (0.61–0.86)a 1.02 (0.95–1.09) 0.95 (0.89–1.02)
  Quartile 4 0.63 (0.51–0.78)a 1.02 (0.96–1.09) 0.91 (0.8–1.03)
Census tract–level percentage of population below poverty level
  Quartile 2 1.05 (0.96–1.15) 0.96 (0.92–1.01) 0.97 (0.92–1.02)
  Quartile 3 1.08 (0.96–1.22) 0.92 (0.88–0.96)a 0.89 (0.83–0.96)
  Quartile 4 1.03 (0.87–1.20) 0.95 (0.90–1.01) 0.84 (0.72–0.98)
Census tract–level percentage of population of black race
  Quartile 2 1.01 (0.95–1.08) 1.01 (0.96–1.06) 0.98 (0.92–1.03)
  Quartile 3 0.96 (0.87–1.07) 1.02 (0.97–1.07) 0.99 (0.93–1.07)
  Quartile 4 1.06 (1.00–1.12) 0.95 (0.88–1.02) 0.87 (0.81–0.94)a
Male sex 0.74 (0.7–0.78)a 1.14 (1.11–1.17)a 1.15 (1.11–1.20)a
Married 1.39 (1.31–1.47)a 1.10 (1.06–1.14)a 1.40 (1.34–1.46)a
Metropolitan area 0.99 (0.92–1.06) 1.01 (0.93–1.09) 0.88 (0.78–0.99)
ap < 0.001.
CI, confidence interval; OR, odds ratio; PET, positron emission tomography.
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overall costs of oral chemotherapy and nonchemotherapy 
prescriptions for patients with cancer.
In conclusion, surgical resection, radiotherapy, and cor-
responding inpatient costs decreased among Medicare with 
NSCLS after the widespread adoption of PET. Consistent with 
previous research, this study suggests that PET has played 
a role in the upstaging of early-stage NSCLC and a corre-
sponding reduction in futile attempts at local control of occult 
metastatic disease. The ability of PET to affect patient man-
agement, health care resource use, and costs remain important 
areas of ongoing research that may change as new treatments 
become available.
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TABLE 4.  Regression Analysis of Inpatient and Total Costs between 1996 and 2005 (n = 43 695)
Characteristic
Relative Change in Percentage of Costs
Inpatient Costs at 
1 Year (95% CI)a
Inpatient Costs at  
4 Months (95% CI)a
Total Costs at  
1 Year (95% CI)a
Year of diagnosis
  1996/1997 1.00 [Reference] 1.00 [Reference] 1.00 [Reference]
  1998 0.99 (0.92–1.06) 0.97 (0.92–1.02) 1.00 (0.94–1.06)
  1999 1.00 (0.94–1.07) 0.98 (0.93–1.04) 1.02 (0.96–1.08)
  2000 0.92 (0.87–0.97) 0.90 (0.87–0.93)b 0.97 (0.93–1.02)
  2001 0.93 (0.89–0.97) 0.90 (0.87–0.93)b 1.02 (0.98–1.06)
  2002 0.99 (0.92–1.07) 0.96 (0.89–1.02) 1.09 (1.03–1.15)
  2003 0.93 (0.86–1.00) 0.88 (0.84–0.91)b 1.09 (1.02–1.17)
  2004 0.92 (0.87–0.98) 0.85 (0.81–0.89)b 1.11 (1.06–1.17)b
  2005 0.94 (0.88–1.00) 0.88 (0.84–0.93)b 1.10 (1.05–1.15)b
Localized disease 1.32 (1.28–1.37)b 1.46 (1.41–1.50)b 1.14 (1.13–1.15)b
Advanced disease 1.03 (0.96–1.10) 1.15 (1.05–1.25) 1.00 (0.97–1.04)
PET facility > 40 miles away 1.00 (0.95–1.04) 1.01 (0.98–1.04) 1.00 (0.97–1.03)
Age > 80 yr 0.84 (0.81–0.87)b 0.88 (0.85–0.91)b 0.81 (0.79–0.83)b
Black race 1.16 (1.11–1.20)b 1.11 (1.09–1.13)b 1.10 (1.08–1.12)b
Comorbid conditions
  1 1.10 (1.08–1.12)b 1.09 (1.06–1.11)b 1.07 (1.05–1.10)b
  >1 1.31 (1.26–1.36)b 1.28 (1.24–1.33)b 1.21 (1.15–1.27)b
Census tract–level percentage of population with less than high school education
  Quartile 2 1.01 (0.97–1.05) 1.00 (0.98–1.02) 1.00 (0.97–1.02)
  Quartile 3 1.02 (0.98–1.06) 1.02 (0.98–1.07) 1.00 (0.96–1.03)
  Quartile 4 1.04 (1.01–1.08) 1.06 (1.02–1.10) 1.00 (0.98–1.03)
Census tract–level percentage of population below poverty level
  Quartile 2 1.01 (0.98–1.04) 1.00 (0.97–1.03) 1.00 (0.99–1.02)
  Quartile 3 1.02 (0.99–1.06) 1.00 (0.98–1.02) 1.01 (0.98–1.04)
  Quartile 4 1.11 (1.03–1.20) 1.10 (1.02–1.18) 1.07 (0.98–1.16)
Census tract–level percentage of population of black race
  Quartile 2 1.01 (0.97–1.05) 1.00 (0.95–1.05) 1.00 (0.97–1.02)
  Quartile 3 1.02 (0.96–1.08) 1.02 (0.96–1.09) 1.01 (0.97–1.04)
  Quartile 4 1.00 (0.94–1.06) 1.01 (0.96–1.07) 0.98 (0.94–1.03)
Male sex 1.04 (1.01–1.07) 1.03 (1.00–1.06) 1.02 (1.00–1.04)
Married 0.96 (0.93–1.00) 0.94 (0.91–0.97)b 1.02 (0.99–1.05)
Metropolitan area 1.09 (0.99–1.19) 1.06 (0.97–1.16) 1.04 (0.99–1.08)
aRelative percentage change in costs = Exp(β – ½σβ
2) – 1 (per Kennedy22).
bp < 0.001.
CI, confidence interval; PET, positron emission tomography.
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apart from his employment at the institution where the study 
was conducted.
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